Intervention not reported
Serious adverse events (such as donor site morbidity, failure of graft including re‐rupture) at 2 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
1 finding from 1 review
Intervention not reported
Treatment failure (graft rupture or ACL reconstruction) at 2 years5 · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
The intervention may leads to lower treatment failure (graft rupture or ACL reconstruction) at 2 years5 (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failure (meniscal surgery) at 5 years5,7 · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
The intervention showed no clear difference in treatment failure (meniscal surgery) at 5 years5,7 (low certainty).
1 finding from 1 review
Intervention not reported
General health‐related quality of life: SF‐36 physical component score (range 0 to 100; higher score = better health state) at 2 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
1 finding from 1 review
Intervention not reported
Return to activity or level of sport at 2 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
The intervention showed no clear difference in return to activity or level of sport at 2 years (low certainty).
1 finding from 1 review
Intervention not reported
Osteoarthritis at 5 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
It is very uncertain whether the intervention changes osteoarthritis at 5 years (very low certainty).
1 finding from 1 review
Participant‐reported scar improvement (long‐term) · people with acne scars
It is very uncertain whether chemical peeling changes participant‐reported scar improvement (long‐term) N of participants… compared with combined chemical peeling plus any active intervention (very low certainty).
1 finding from 1 review
Participant‐reported scar improvement (short‐term) · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Investigator‐assessed adverse events (short‐term) · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed adverse events (short‐term) N of participants with adverse events · people with acne scars
It is very uncertain whether chemical peeling changes participant‐assessed adverse events (short‐term) N of participants… compared with combined chemical peeling plus any active intervention (very low certainty).
1 finding from 1 review
Participant satisfaction · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐ 8 weeks · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review